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Immunological adjuvants are defined as agents which act nonspecifically to enhance 
immune responsiveness to a  specific antigen. While many substances  are  known  to 
have  adjuvanticity,  remarkably little  is understood  about the mechanism by which 
they enhance either the antibody response or cellular immunity. It is now clear, for at 
least  some antigens, that interaction of three cell types is required  for antibody for- 
mation: thymus-derived lymphocytes (T cells),  bone marrow-derived lymphocytes (B 
cells),  and probably macrophages. In studies on the specificity of response to hapten- 
protein  conjugates, it has emerged that the specificity of the  antibody-producing  cell 
(hapten specific)  is generally not the same as that of the T  cell which bears immu- 
nological memory (carrier specific)  (1-3). In addition,  the characteristics of the helper 
cell involved  in  antibody  formation,  i.e.  thymus  derived,  nonantibody  secreting, 
carrier specific,  and  nondividing,  appear  at present  indistinguishable  from  those of 
the thymus-derived lymphocyte responsible for cell-mediated immunity (4). 
We  chose  to pursue  this  analogy by exploring  the  effects of the  two most 
effective  immunological  adjuvants  in  mice,  pertussis  vaccine  and  tubercle 
bacilli,  the latter  at least, known also to engender delayed-type  hypersensitiv- 
ity. The in vitro immunization system  developed by Mishell  and  Dutton  (5) 
permitted us to study the effect of adjuvant on a primary in vitro response to 
sheep erythrocytes (SRBC). 
We have posed the following  questions:  (a)  Will  spleen  cells from animals 
primed with  adjuvant  give an enhanced  in vitro primary response against  an 
irrelevant antigen,  SRBC?  (b) If so, what is the mechanism by which the adju- 
vant-primed cells enhance  this in vitro response?  (c) Which  cell is responsible 
for the adjuvant  effect and upon what cell does this cell act? 
Materials and Methods 
The adjuvants used in this study were Bordetdla pertussis vaccine, fluid, USP (E. Lilly & 
Co., Indianapolis,  Ind.)  containing  8 antigenic  units  (AU/ml (equivalent  to no fewer than 
6.4 X  101° standard pertussis  organisms/ml).  For use in vitro, the organisms were dialyzed 
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against saline or w~shed by centrifugation to remove the preservative. The tubercle bacilli 
were of two types, seemingly not significantly different in their action. BCG, Phipps strain 
(TMC 1029), and Mycobacterium tuberculosis, R1RV (TMC 205), a human avirulent  organism, 
were generously provided by the Trudeau Institute, Saranac Lake, N. Y., and grown in Dubos 
albumin-Tween medium to a density of approximately 5 X 108-2 X  109 viable organisms/cc. 
The BCG were killed by heating, and one batch of R1Rv with a count of no greater than 
5 X  I0  ~  was used. Purified protein derivative was obtained from the Ministry of Agriculture, 
Central Veterinary Laboratories, Weybridge, England. 
B6D2F1 (C57BL/6 X DBA/2) mice  were immunized once with intraperitoneal  (0.4 AU) 
and subcutaneous inoculation (0.4 AU) in two ranks of B. pertussis  or the killed equivalent 
of 4-10 X  107 tubercle bacilli. Mice were used between 3 and 5 wk after immunization. 
Spleen cultures were prepared in the manner described by Mishell and Dutton (5) enriched 
in Eagle's  minimal essential medium and 7% fetal  calf serum  (Reheis Co., Inc.,  Berkley 
Heights, N. J.; lot No. 21806). The cells were cultured at 7 X  106 cells/cc in Falcon plastic 
Petri dishes (Falcon Plastics,  Div. B-D  Laboratories,  Inc.,  Los Angeles, Calif.; catalogue 
3001) to which were added 25 t~l of a 2% SRBC suspension, and gassed with a mixture con- 
taining 7% 02, 10% CO2, 83% nitrogen. All cultures were fed daily with nutrient medium, 
and the numbers of direct plaque-forming cells (PFC) was  assayed on days 3 or 5 by the 
Jerne  plaque assay in 0.5% agarose. The results are expressed as plaque-forming ceils per 
106 recovered cells, as determined by an appropriately  calibrated  Coulter counter  (Coulter 
Electronics, Inc., Hialeah, Fla.). Dilutions of pertussis vaccine or PPD were added usually 
on day 0 to adjuvant-primed and normal spleen cultures. All cultures were made in duplicate, 
and each sample was plated at two dilutions, each in duplicate. Thus an average of four or 
eight plates was counted for each sample. 
RESULTS AND  CONCLUSIONS 
When adjuvant-primed cells were cultured with  SRBC,  a  normal primary 
in vitro response ensued (Table I). However, when specific adjuvant to which 
the donors were primed was added to the cultures, an enhanced response was 
obtained, which is described by an adjuvant index (A.I.), i.e., the ratio of the 
response to SRBC in the presence of adjuvant compared with the response of 
the same cells with no adjuvant added in vitro. The maximal adjuvant effect 
of a  2-3-fold stimulation in the culture system described was obtained on the 
3rd day. While the number of PFC was greatest on the 5th day, the adjuvant 
effect was less marked.  The degree of enhancement was  affected by the dose 
of adjuvant added to the cultures; higher doses of adjuvant were often found 
to be toxic. The enhancement produced by adjuvants added in vitro was de- 
pendent on  specific prior priming of  the  donor spleens,  rather  than  on  any 
nonspecific effect  on lymphoid cells, since the adjuvants did not enhance sig- 
nificantly the response to SRBC of unprimed cells. Lastly, the adjuvant effects 
were specific in the sense that cultures of primed cells were significantly stimu- 
lated only by the adjuvant in vitro related to that used for priming, although 
slight cross-stimulation by PPD is seen on pertussis cells, which might perhaps 
be expected on the basis of common endotoxin activity. 
In  cell-mediated immunity it  has  been  shown  that  soluble mediators  are 
produced  by  sensitized lymphocytes upon interaction with  antigen in vitro 
(4).  Since the  enhanced response of  adjuvant-primed spleens depended upon 
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mediators  in  delayed-type  hypersensitivity,  experiments  were  designed  to 
ascertain whether  adjuvant-primed  cells produced a  soluble mediator which 
could enhance the response of normal cells  to SRBC. Spleen cells from adju- 
vant-primed mice were cultured as described above with antigen, B. pertussis, 
at 10  -4 AU/ml or PPD at 25 #g/ml. At 20 hr, the cells were removed and the 
supernatant  harvested.  These were then  added  in  three dilutions to normal 
spleen cells  together with sheep erythrocytes and cultured for 3 days. As can 
be seen in Table II, supernatants of adjuvant-primed cells stimulated in vitro 
with the specific adjuvant did enhance the primary response of normal  cells 
to SRBC. Moreover, when the response produced by the supernatants of per- 
tussis-primed spleens was compared with that produced by the control super- 
TABLE I 
Primary In  Vitro  Response to SRBC  of Adjuvant-Primed  and  Normal  Spleen  Cells 
Adjuvant in  Day 3 response  A,I.:~  Day 5 response  A.I.J;  Priming of donor  vitro 
PFC/IO  4 ceUs* .4- sE  PFC/IO~ cells* d: sB 
Pertussis  None  --  20.3  ±  1.2  (11)  1.00  669  4-  I01  (7)  1.00 
Pertussis  1.0-0.2  X  10-4AU  40.1  4-  2.9  (11)  1,97  298  ±  34  (7)  0.45 
4.0-0.8  X  10-~AU  75.5  :t:  3.7  (5)  3.72  824  4-  142  (5)  1.23 
PPD  25#g  33.4  -4-  2.5  (7)  1.64 
Tubercle bacilli  None  --  53.8  ±  8  (5)  1.00  500  4-  65  (8)  1.00 
PPD  25#g  129  ±  20  (5)  2.40  454  ±  38  (8)  0.91 
5/zg  86.0±  9  (5)  1.60  617  4-  91  (4)  1.22 
Pertussis  1.0-2.2  X  10  -s AU  36.7  -4-  3.7  (4)  0.68 
None  None  --  30,1  4-  2.4  (7)  1.00  879  -4-  153  (4)  1.00 
Pertussis  1.0--0.2  X  10  TM AU  30.1  -4-  2,0  (7)  1.00  336  4-  71  (4)  0.38 
4.0-0.8  X  10  -5 AU  45.5  -4-  5,5  (3)  1.52  788  4-  197  (3)  0.89 
None  --  36.0  4-  9,1  (3)  1.00  631  4-  74  (5)  1.00 
PPD  25/~g  46.0  4-  10  (3)  1.28  582  4-  72  (5)  0.92 
5/~g  40.3  4-  12  (3)  1.11  662  -4-  109  (4)  1.05 
* Numbers in parentheses indicate the number of experiments. 
~; A.I.  adjuvant index. 
natants  of  normal  spleen  cultures  cultured  with  pertussis,  a  dose-response 
relationship was observed in the adjuvant index. In our experience, the adju- 
vant effect of pertussis-primed spleens was greater and more reproducible than 
that for PPD-stimulated tubercle bacilli-primed spleens.  In  the  case of per- 
tussis,  a  given  supernatant stimulated  strongly about  two of  three  normal 
spleens on which it was tested, while,  for a  given normal spleen,  the optimal 
amount of  active  supernatant  required  to  produce  maximal  enhancement 
similarly varied from spleen to spleen. It appeared in the case of pertussis that 
the degree of adjuvanticity for normal spleens of the active supernatants was 
of  the  same  order  as,  or  only slightly  less  effective than  that of adjuvant- 
primed spleens. 
Lastly, we have tried to ascertain  the  cell type responsible for producing 
this  supernatant  factor  and  that  upon  which  it  acts  by means  of  a  mouse 
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of Cerottini et al. (6). Spleen cells were incubated at 37°C for 45 rain at a final 
concentration of 107  cells/ml containing anti-0 serum and rabbit complement, 
both at 1/18. The average per cent cytotoxicity in four experiments was approxi- 
mately 27 %.  Pertussis-primed cells were treated with anti-0 serum or normal 
AKR mouse serum in parallel, and cultured with pertussis. At 20 hr superna- 
rants were assayed for adjuvant±city (Table IIIA). In these experiments it ap- 
peared  that  the  anti-0  treatment  completely abrogated  the  adjuvant  effect, 
i.e. production of supernatants  that enhanced the primary response of normal 
spleens, while normal mouse serum had no effect. In an additional four experi- 
TABLE  II 
Enhancement of I~ Vitro Response to SRBC of Normal Spleen Cells By Supernatants 
of Adjuvant-Primed Spleen Cells 
Vol. supern.  Supern. of pertussis-primed ceils  Supern. of normal cells cultured  A.I.§ 
cultured with pertussls*  with pertussis* 
m  PFC/IO  6 cells :k SE 
0.2  166  4-  17  73  -4-  8  2.27 
0.1  109  4-  8  62  -4-  7  1.76 
0.05  100  4-  14  136  4- 36  0.76 
0  73  -4-  7  73  4-  7  1.00 
Supern. of Tbc,-primed cells  Supern. of normal cells cultured 
cultured with PPD~  with PPD~ 
0.2  111  4-  7  120  ±  45  0.92 
0.1  105  -4-  8  121  4-  16  0.86 
0.05  217  -4-  16  125  ±  36  1.73 
0  105  -4-  12  121  -4-  13  0.87 
* 4 supernatants were examined in 10 trials, excepting at 0.05 ml where 3 were tested in 
6 trials. 
:~ 4 supernatants were examined in 6 trials, excepting  at 0.05 ml where 2 were tested in 
3 trials. 
§ Adjuvant index, in this case, is given by PFC (supern. of primed cells +  adjuvant)/PFC 
(supern. of normal cells +  adjuvant). 
ments,  active supernatants  from  pertussis-primed spleens were  added  to cul- 
tures  of normal  cells which had  been  pretreated either with  anti-0 or normal 
AKR mouse sera (Table III B). The data indicate that the supernatant factor 
was capable of exerting an adjuvant effect equally well on spleens deficient of 
T  cells. These results suggest that it is the T  cell which carries specific informa- 
tion for adjuvant priming and which produces the soluble factor which mediates 
the  effect.  Moreover,  they  suggest  that  this  mediator  affects  either  B  cells 
directly or macrophages,  rather  than  T  cells in  the  recipient population,  al- 
though  clearly all T  cell function  was  not  abolished in  controls after  anti-0 
treatment. The studies described confirm the observations of Allison and Davies 
(7) that the adjuvants studied here in the mouse, pertussis and tubercle bacilli, 
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gether with  the work of Dutton et al.  (8)  they demonstrate  that the Mishell- 
Dutton in vitro system provides a  remarkable  tool for studying the effects of 
immunological  priming with  related,  unrelated  antigens  and  adjuvants.  They 
confirm and extend the findings of Rubin and Coons  (9)  which indicated  that 
spleen  cells of mice primed to tetanus  toxoid show enhanced primary in vitro 
responses  to SRBC  on day 5 when the specific protein is added to the culture 
on day 2. Perhaps  because  of  the  antigenic  complexity  of  the  pertussis,  the 
degree of enhancement here is two to five times greater. They further support 
the finding  that T  cells  can produce a  soluble factor(s)  after mixed leukocyte 
cultures  (8),  or from incubation with  antigen  (10-12)  which  can  replace  T 
cells  in  a  primary in vitro response. 
TABLE III 
Eject of Anti-O Serum on Production  and Action of Enhancing Supernatants 
A.I.* 
Primed cells treated  with 
A.  Effect on cells producing supernatants  NMS$ 
Supernatants  from normal cells cultured  1.00 (control) 
with pertussis (0.2 ml) 
Supernatants  from pertussis-primed cells  2.30  4-  .22 
cultured with pertussis (0.2 ml) 
Normal cells treated  with 
B.  Effect on normal cells exposed to enhancing  NMS 
supernatants 
Supernatants  from normal cells cultured  1.00  (control) 
with pertussis (0.2 ml) 
Supernatants  from pertussis-primed cells  3.37  -4- 0.81 
cultured with pertussis (0.2 ml) 
Anti-0 
1.09  4-  0.04 
1.02  ±  0.11 
Anti-0 
0.59  ±  0.08 
3.36  4-  0.90 
* A.I., adjuvant index =  PFC (experimental culture)/PFC  (control culture). 
$ NMS, normal mouse serum. 
While  it  may  be  tempting  to  speculate  about  the  role  of  such  a  soluble 
mediator in vivo, the system is really too complex to allow simple interpreta- 
tion. It must be recognized that the rocking cultures of the in vitro  immuniza- 
tion  system  bear  little  resemblance  to  the  tight  architecture  of  a  lymphoid 
organ where  diffusion of molecules from cell  to cell must be quite  restricted. 
Further,  it is probable that a  variety of factors are produced,  as in the case of 
cell-mediated immunity, of which some may be  stimulatory and  others  toxic. 
This might explain why a greater effect was seen at day 3 rather than day 5. 
These observations indicate that the effects of immunological adjuvants can 
be studied effectively in vitro, and that some adjuvants may not indeed act so 
nonspecifically as previously believed (13), but rather by virtue of an immuno- 
logically  specific  T  cell  response  to  antigenic  portions  of  these  adjuvants. 
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cell-mediated immunity,  when  stimulated by the  specific antigen  can  act  by 
producing a  soluble mediator(s) which affects B  cells or perhaps inacrophages. 
They do not,  however,  imply that  the soluble mediator is the sole mechanism 
by which T  cells can exert a  cooperative effect on B  cells. 
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